Goldman Sachs acknowledges Merck & Co., Inc. (MRK) as a high consensus ROE stock. The consensus regards it as a promising long-term investment with strategic acquisitions making it a potential buy. The successful Q2 leads to recommendations for investors to pick the stock at $115. An investment firm, Stratos Wealth Advisors LLC has a $4.39 million stock position in Merck. Analysts indicate a 20% gain while being selected by many hedge funds as promising. Billionaire Ray Dalio regards the stock as one of the best cheapest buys.
Merck's stock continues to attract investor attention despite varying performance in the market. The stock is backed by the strength of KEYTRUDA sales that significantly boost their revenue growth. Despite a 9% fall and a cut in guidance, there are still optimistic views on its future potential. Consequently, it is viewed as a potentially good beginner stock and an attractive blue chip dividend stock to buy. However, the cancellation of a promising cancer drug trial led to a 10% drop for Germany’s Merck Group.
Merck Stocks MRK News Analytics from Thu, 25 Apr 2024 07:00:00 GMT to Sat, 19 Oct 2024 15:57:20 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor -3